CYAD News and Press, Celyad SA From 07/20/21

Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×10 6 cells per infusion) with no Graft-versus-Host disease reported to date Submission of IND application ...

MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a R...

MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Chief Scien...

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Presents Corporate Update at EHA 2021 - Slideshow

undefined/iStock via Getty Images As per the preliminary data, CYAD-211 shRNA-based allogeneic CAR T candidate developed by Celyad Oncology ([[CYAD]] -3.7%) has indicated a mixed safety profile based on an early-stage trial for patients with relapsed/refractory multiple myeloma (r/r MM). Resu...

Treatment with CYAD-211 generally well-tolerated at first two dose levels, with no evidence of Graft-versus-Host Disease observed Two partial responses observed among five evaluable patients Cell engraftment of CYAD-211 observed in all patients from dose level 2, with ev...

Ra Medical Systems (RMED) +56%.Liminal BioSciences (LMNL) +42%.NextDecade Corporation (NEXT) +30%.U.S. Concrete (USCR) +28% as Vulcan Materials buys the Company in $1.3B deal.QTS Realty Trust (QTS) +20% on being acquired by Blackstone funds for $78/share.ChromaDex Corporation (CDXC)...

MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company ...

MONT-SAINT-GUIBERT, Belgium, May 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has recei...

Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT) +15%.Heron Therapeutics (HRTX) +15% on...